As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Rigel Pharmaceuticals, Inc. The largest reported stake is Soleus Capital Master Fund, L.P.'s, at 9.9%. 10 filings are on record since August 5, 2025 (Schedule 13G/A, August 13, 2026).
Who owns Rigel Pharmaceuticals Inc.?
Sell to companies like Rigel Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 1,672,000 · Sole dispositive: 0 · Shared dispositive: 1,672,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Soleus Capital Master Fund, L.P. · Sole voting: 0 · Shared voting: 1,843,504 · Sole dispositive: 0 · Shared dispositive: 1,843,504 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Armistice Capital, LLC · Percent: 6.93% · SCHEDULE 13G
- · Holder: Soleus Capital Master Fund, L.P. · Percent: 5.2% · SCHEDULE 13G
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Rigel Pharmaceuticals, Inc. has 10 Schedule 13D or 13G filings on record since 2025-08-05. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 9.9% | 1,843,504 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Armistice Capital, LLC | 8.95% | 1,672,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| State Street Corporation | 6% | 1,091,223 | SCHEDULE 13G, 2026-02-09 | 2025-12-31 |
| 0.7% | 116,406 | SCHEDULE 13G/A, 2025-10-07 | 2025-09-30 | |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Rigel Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Rigel Pharmaceuticals, Inc. and the records around it.
Rigel Pharmaceuticals, Inc. elsewhere on the record
Companies that share a holder
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
- Morgan Stanley also filed stake reports on 182 other companies: MDA Space Ltd. (Nov 2026), RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (Oct 2026), Arbutus Biopharma Corp (Oct 2026)
Watch Rigel Pharmaceuticals, Inc.
Get an email when Rigel Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Rigel Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Rigel Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rigel Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 0 | 1,843,504 | 0 | 1,843,504 | SCHEDULE 13G/A, 2026-08-13 |
| Soleus Capital, LLC | 0 | 1,843,504 | 0 | 1,843,504 | SCHEDULE 13G/A, 2026-08-13 |
| Soleus Capital Group, LLC | 0 | 1,843,504 | 0 | 1,843,504 | SCHEDULE 13G/A, 2026-08-13 |
| Soleus Capital Management, L.P. | 0 | 1,843,504 | 0 | 1,843,504 | SCHEDULE 13G/A, 2026-08-13 |
| Soleus GP, LLC | 0 | 1,843,504 | 0 | 1,843,504 | SCHEDULE 13G/A, 2026-08-13 |
| Guy Levy | 0 | 1,843,504 | 0 | 1,843,504 | SCHEDULE 13G/A, 2026-08-13 |
| Armistice Capital, LLC | 0 | 1,672,000 | 0 | 1,672,000 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 1,672,000 | 0 | 1,672,000 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Rigel Pharmaceuticals, Inc. by CUSIP 766559702 and gives its principal executive office as 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Soleus Capital Master Fund, L.P. | 3.7% | SCHEDULE 13G/A |
| 2025-08-14 | Armistice Capital, LLC | 8.92% | SCHEDULE 13G/A |
| 2025-10-07 | Morgan Stanley | 0.7% | SCHEDULE 13G/A |
| 2025-11-14 | Armistice Capital, LLC | 3.99% | SCHEDULE 13G/A |
| 2026-02-09 | State Street Corporation | 6% | SCHEDULE 13G |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-07 | Soleus Capital Master Fund, L.P. | 5.2% | SCHEDULE 13G |
| 2026-05-15 | Armistice Capital, LLC | 6.93% | SCHEDULE 13G |
| 2026-08-13 | Soleus Capital Master Fund, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-08-14 | Armistice Capital, LLC | 8.95% | SCHEDULE 13G/A |
Questions about who owns Rigel Pharmaceuticals, Inc.
Who owns Rigel Pharmaceuticals, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Rigel Pharmaceuticals, Inc.: Soleus Capital Master Fund, L.P. (9.9%, Schedule 13G/A, filed 2026-08-13), Armistice Capital, LLC (8.95%, Schedule 13G/A, filed 2026-08-14) and State Street Corporation (6%, Schedule 13G, filed 2026-02-09).
Who are the largest shareholders of Rigel Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Rigel Pharmaceuticals, Inc. on this page are Soleus Capital Master Fund, L.P. (9.9%), Armistice Capital, LLC (8.95%) and State Street Corporation (6%).
When did Soleus Capital Master Fund, L.P. buy into Rigel Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Soleus Capital Master Fund, L.P. on this page is the Schedule 13G/A, filed 2025-08-05, reporting 3.7%; its latest, Schedule 13G/A filed 2026-08-13, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Rigel Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.